Luminex announced that the U.S. Food and Drug Administration (FDA) has cleared labeling updates for the company’s xTAG Respiratory Viral Panel (RVP) to include data about the performance of the test in humans infected with the pandemic strain of influenza A, 2009 influenza A/H1N1. The test’s labeling has been updated to include information from two new studies that demonstrate that xTAG RVP can be an effective aid in the detection of 2009 Influenza A/HIN1, but cannot identify the hemagglutinin gene of the 2009 Influenza A/H1N1 in clinical specimens. xTAG RVP can simultaneously detect 12 respiratory viruses and subtypes, including influenza A with subtyping, at the DNA/RNA level. Luminex Corp., 888-219-8020, www.luminexcorp.com